Description
Vitae Pharmaceuticals, Inc. is a clinical stage biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. The Company’s product candidates include VTP-34072, VTP-37948, VTP-4374, VTP-38443 and VTP-38543. VTP-34072 is being developed for type II diabetes. VTP-34072 is designed to inhibit 11b hydroxysteroid dehydrogenase type II, or 11b HSD1, the enzyme responsible for production of cortisol in tissues where active glucose metabolism takes place, including the liver and adipose, or fat, tissue. VTP-37948 is being developed for treatment of Alzheimer's. Alzheimer's is characterized by the accumulation of extracellular protein deposits in the brain that are called amyloid plaques.
Address
502 W Office Center Dr
FORT WASHINGTON, PA 19034-3215
United States
FORT WASHINGTON, PA 19034-3215
United States
Website
http://vitaepharma.comKey stats and ratios
| Q3 (Sep '14) | 2013 | |
| Net profit margin | -29.29% | 5.16% |
| Operating margin | -27.80% | 9.73% |
| EBITD margin | - | 10.64% |
| Return on average assets | -16.05% | 3.35% |
| Return on average equity | - | - |
| Employees | 49 |
No comments:
Post a Comment